繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Artiva Biotherapeutics Reports Wider Q2 Loss, No Revenue

2024-08-30 05:31

05:31 PM EDT, 08/29/2024 (MT Newswires) -- Artiva Biotherapeutics (ARTV) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier.

Four analysts surveyed by Capital IQ expected a loss of $4.40.

No revenue for the quarter ended June 30 was reported. Revenue a year earlier was $3.5 million.

Four analysts polled by Capital IQ estimated $80,000.

As of June 30, the company said it had $46.6 million in cash, cash equivalents, and short-term investments. It said the $179 million in gross proceeds from its initial public offering in July extends cash runway at least through the end of 2026 and through key clinical data milestones.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。